Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Careium: A clean beat with no asterisks - ABG

CAREThird party research22.10.2026, 08.24

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Q3 sales 6% above our ests. at SEK 260m, for 20% org. growth
* EBITA SEK 27m vs. ABGSCe 20m
* Trading at 9x-7x '27e-'28e EV/EBITA adj.

An unexpected, but welcome, double-digit margin

The Q3 report came in above our estimates for both sales and earnings, and the report was strong across the board. Careium delivered sales of SEK 260m (6% vs ABGSCe 245m), corresponding to y-o-y organic growth ex. FX of 20% (6.4pp vs ABGSCe 13.5%). Segment wise, service sales was SEK 188m (7% vs ABGSCe 175m), and product sales was SEK 73m (4% vs ABGSCe 70m). Regionally, the Nordics grew 26% (service 27%, driven by Asker and Baerum in Norway), the UK & Ireland 15% (service 35%, product -6%), the Netherlands 33% (product sales SEK 5.7m vs 0.8m) and Other markets 22%. The gross margin increased to 45% (0.4pp vs ABGSCe 44.6%). The cost base was in line with expectations, with opex of SEK -90m (1% vs ABGSCe -89m), reminding us of the scalability in the business model. As such, adj. EBIT amounted to SEK 27m (33% vs ABGSCe 20m), for a margin of 10.3% (2.1pp vs ABGSCe 8.2%), vs. 8.8% Q3'25. FCF was SEK 14m, held back by a SEK 24m working capital build, mainly inventories and receivables. This was a touch lower than our estimates, but roughly in line with general Q3 expectations.

Mix and pricing do the work

With all four regions growing double digits and gross profit up in every one of them, the operating leverage we have been waiting for is showing up. The Nordic gross margin step-up suggests the upfront cost of the Norwegian onboarding has largely rolled off, in line with what management hinted at in Q2. Service sales grew 27% on connections up only 8% (344.5k), pointing to mix and pricing rather than volume alone. We also note that the margin is improving despite material R&D expenses, up ~60% YTD. We also note that the hybrid loan to Doro was settled in the quarter (SEK 35m repaid, SEK 29m written off to retained earnings, no P&L effect), which lifts net debt to SEK 191m (183m).

Consensus EBIT estimates likely up HSD

The share is up ~12% YTD, but is down ~10% since the Q2 report. On our unrevised estimates, the share is trading at 9x-7x ‘27e-'28e EV/EBITA adj. The positive mechanical effect for consensus '26e-'28e EBIT should be within a high-single-digit range. We hope to get more details during the conference call at 10.30 CET. Link to the webcast here.